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Background: The outcome of adrenalectomy carried out by laparoscopy or open surgery for solid tumor 
metastases was assessed.
Methods: A total of 317 patients with histologically confirmed adrenal metastatic disease collected from 
30 centres in Europe underwent adrenalectomy by laparoscopy (n=146) or open laparotomy (n=171). 
Differences between laparoscopic and open adrenalectomy were assessed by a single Cox analysis for both 
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Introduction
Several studies have reported that adrenalectomy improves 
outcome in selected patients with metastatic disease, 
particularly in cases of isolated lesions and metachronous 
metastasis (1-6). In patients with isolated adrenal metastases, 
a more favourable survival for adrenal resection has been 
reported as compared with nonoperative approaches (7,8). 
Adrenal metastasis is often confined within the gland itself, 
providing more chances to achieve en bloc removal. In the 
context of established indications for surgical extirpation of 
adrenal masses, laparoscopic adrenalectomy has become the 
gold standard for removal of most benign tumours and may 
be used for malignant lesions as well (9-12). 
The laparoscopic approach has improved immediate 
surgical results as compared to the open procedure for 
the treatment of benign tumours, with the advantages of 
less blood loss, minimal invasion, quicker recovery, fewer 
complications, and shorter duration of hospitalization 
(13-16). However, there is much less experience regarding 
the use of laparoscopic adrenalectomy in metastatic adrenal 
disease. Adrenalectomy though the laparoscopic route as 
compared with open surgery achieves similar oncological 
results with less morbidity (17,18), but homogeneous 
patient-based series comparing outcome differences 
between laparoscopic and conventional open adrenalectomy 
in patients metastatic adrenal disease are needed.
In a previous study of patients undergoing adrenalectomy 
for solid tumor metastasis included in a European 
multicenter survey, long-term survival in selected patients 
was shown after operative removal of adrenal metastasis (4). 
This retrospective study performed in the same population 
was designed to assess the outcome in oncological terms 
of removal of adrenal metastasis by laparoscopy or open 
surgery.
Methods
The design and characteristics of the study has been 
previously described (4). Briefly, this was a retrospective 
and multicenter survey with data provided by Units of 
Endocrine Surgery of 30 hospitals from UK, Italy, France, 
Germany, Serbia, and Spain. From 1999 to 2001, all 
consecutive patients with metastases to the adrenal gland in 
which adrenalectomy could be successfully performed, with 
histologically proven malignancy were included. Patients 
with primary renal tumors involving the adrenal glands and 
those in which the time elapsed between adrenalectomy 
to the last follow-up visit was not specified were excluded. 
This study aimed to assess the outcome of laparoscopic 
adrenalectomy vs. open adrenalectomy.
An ad hoc questionnaire was completed over 1-year period 
(July 2010–2011) with clinical information collected from 
medical records, including demographics, primary tumor-
related data, diagnostic techniques, side of the adrenal 
procedures.
Results: The median overall survival was 24.0 [95% confidence interval (CI): 21.4–26.6] months for open 
adrenalectomy and 45.0 (95% CI: 22.6–67.4) for laparoscopic adrenalectomy (P=0.008). Survival rates 
were 68%, 49%, 35% and 29% at 1, 2, 3 and 5 years for open surgery vs. 88%, 62%, 52% and 46% for 
laparoscopy, respectively. In the subgroup of R0 resections, the difference in survival in favor of laparoscopy 
(median 46 vs. 27 months) was marginally significant (P=0.073). Renal cancer [hazard ratio (HR) 0.42; 
95% CI: 0.23–0.76, P=0.005], surgery of the primary tumor (HR 0.33; 95% CI: 0.19–0.54), and use of 
chemotherapy (HR 0.62; 95% CI: 0.43–0.88) were associated with a better survival, whereas type of resection 
(R1/R2 vs. R0) was associated with a worse prognosis (HR 2.29; 95% CI: 1.52–3.44, P<0.001).
Conclusions: Laparoscopic adrenalectomy patients showed a longer survival than open adrenalectomy 
individuals, as minimally invasive approach was attempted more common in less advanced disease which led 
to higher number of R0 resections.
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mass, extra-adrenal disease extension, type of surgical 
approach (laparoscopy vs. open laparotomy), completeness 
of resection (R0, complete resection, R1, microscopic 
margin involvement, R2, gross macroscopic tumor); 
isolated adrenalectomy (limited to the adrenal gland), 
extended adrenalectomy (resection of contiguous organs 
with lymphadenectomy), duration of surgical procedure, 
length of hospitalization, postoperative complications, 
adjuvant chemotherapy, size of the tumor, length of follow-
up, and vital status at the last follow-up control. When the 
laparoscopic approach was converted to a laparotomy, these 
cases were considered as open.
In all cases, histopathologic reports were reviewed. 
Metastases detected at ≤6 and >6 months after treatment 
of the primary tumor were classified as synchronous and 
metachronous, respectively. In patients treated with bilateral 
adrenalectomy in different procedures, the type of surgery 
and outcome of the first adrenalectomy was analyzed. 
Overall survival was defined as the time from adrenalectomy 
up to the date of the last follow-up or death. 
Statistical analysis
Categorical variables are expressed as frequencies and 
percentages, and continuous variables as mean and standard 
deviation (± SD). Follow-up time and survival time are 
expressed as median values and interquartile range (IQR) 
(25th–75th percentile). The Kaplan-Meier method was used 
to estimate survival, with median values and 95% confidence 
intervals (CIs) for 1, 2, 3, and 5 years survival rates. Survivals 
for the different surgical procedures (laparoscopy vs. open 
laparotomy) and for the subset of patients who underwent 
R0 resections were also estimated with the Kaplan-Meier 
method, with differences analyzed with the log-rank test. 
Bivariate Cox analysis was used to assess the relationship 
between each variable with survival. Data are expressed 
as hazard ratio (HR) and 95% CI. Variables statistically 
significant or marginally significant in the bivariate analysis 
were analyzed in a Cox proportional hazards regression 
model with backward stepwise selection. Statistical 
significance was set at P<0.05. Data were analyzed using the 
SPSS statistical program (version 18.0) (IMB Corp.).
Results
The study population included 317 patients, 171 (53.9%) 
undergoing open adrenalectomy and 146 (46.1%) 
laparoscopic adrenalectomy. Table 1 shows relevant 
characteristics of patients in the two study groups. 
Statistically significant differences in the laparoscopic 
adrena lec tomy  group  a s  compared  to  the  open 
adrenalectomy group included higher percentages non-small 
cell lung cancer (NSCLC) and colorectal cancer patients; 
chemotherapy treatment; use of computed tomography 
(CT) scan only or positron emission tomography (PET) for 
diagnosis; a lower percentage of bilateral adrenal metastases; 
higher percentages of isolated adrenalectomy, R0 resections; 
shorter duration of operation and hospitalization; smaller 
tumor size; and higher percentage of adjuvant-treated 
patients. The median (IQR) length of follow-up was 21 
[8–36] months for open adrenalectomy and 20 [10–35] for 
laparoscopic adrenalectomy. 
As shown in Table 2, in the bivariate analysis, renal cancer 
as the type of primary tumor and surgical treatment were 
significantly associated with a better survival, whereas the 
presence of synchronous adrenal metastasis, extra-adrenal 
disease, extended adrenalectomy, R1/R2 resections, duration 
of surgery, tumor size, length of hospital stay, and open 
surgery (or converted) were associated with poor survival. 
In the multivariate Cox proportional hazards regression 
model (Table 2), risk factors for better survival were renal 
cancer (HR 0.42; 95% CI: 0.23–0.76, P=0.005), surgery of 
the primary tumor (HR 0.33; 95% CI: 0.19–0.54), and use 
of chemotherapy (HR 0.62; 95% CI: 0.43–0.88), whereas 
type of resection (R1/R2 vs. R0) was associated with a worse 
prognosis (HR 2.29; 95% CI: 1.52–3.44, P<0.001). Open 
adrenalectomy (or converted) almost reached statistical 
significance (HR 1.37; 95% CI: 0.971–1.925, P=0.073).
The median (IQR) survival for the laparoscopy group was 
45.0 (22.6–67.4) months as compared with 24.0 (21.4–26.6) 
months for the open adrenalectomy group (log-rank test, 
P=0.008) (Figure 1). In patients treated with laparoscopic 
adrenalectomy, the survival rates at 1, 2, 3, and 5 years were 
88.4%, 62.4%, 52.0%, and 46.0%, respectively. In patients 
treated with open adrenalectomy, the survival rates were 
67.9% at 1 year, 49.0% at 2 years, 35.3% at 3 years, and 
29.2% at 5 years.
The median survival analysis in the subset of patients 
undergoing R0 resections was 46 (95% CI: 13.695–78.305) 
months for laparoscopy-treated patients and 27.0 (95% CI: 
18.063–35.937) for laparotomy-treated patients (log-rank 
test, P=0.073).
Discussion
Results of the present study show a better survival for 
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Table 1 Salient data of 317 patients with adrenal metastatic disease treated with open adrenalectomy and laparoscopic adrenalectomy
Variable Open surgery (n=171) Laparoscopy (n=146) P value
Gender 0.750
Men 119 (69.6) 104 (71.2)
Women 52 (30.4) 42 (28.8)
Age, years, median (IQR) 58 [50-67] 60 [54-65] 0.427
Type of primary tumor 0.027
Non-small cell lung cancer 69 (40.4) 79 (54.1)
Colorectal cancer 21 (12.3) 22 (15.1)
Renal cancer 23 (13.5) 14 (9.6)
Breast cancer 2 (1.2) 9 (6.2)
Melanoma 5 (2.9) 6 (4.1)
Other* 51 (29.8) 16 (10.9)
Treatment of the primary tumor
Surgery 155 (90.6) 128 (87.7) 0.394
Chemotherapy 54 (31.6) 92 (63.0) <0.001
Radiation therapy 29 (17.0) 43 (29.5) 0.008
Synchronous adrenal metastasis (n=310) 44 (26.5) 29 (20.1) 0.188
Metachronous adrenal metastasis (n=310) 122 (73.5) 115 (79.9)
Diagnostic method of adrenal mass <0.001
CT scan only 147 (86.0) 105 (72.4)
MRI only 10 (5.8) 3 (2.1)
PET only 3 (1.8) 9 (6.2)
FNA 1 (0.6) 0
CT and/or MRI and/or PET 10 (5.8) 28 (19.3)
Extra-adrenal disease (n=296) 46 (30.3) 37 (25.7) 0.382
Site of the adrenal metastasis (n=314) 0.006
Right adrenal gland 70 (41.2) 81 (56.2)
Left adrenal gland 89 (52.4) 61 (42.4)
Bilateral 11 (6.5) 2 (1.4)
Surgical-related data
Type of resection (n=281) <0.001
Isolated adrenalectomy 100 (71.9) 131 (92.3)
Extended adrenalectomy 39 (28.1) 11 (7.7)
Completeness of resection 0.014
R0 139 (81.3) 135 (92.5)
R1† 10 (10.5) 7 (4.8)
R2† 14 (8.2) 4 (2.7)
Duration of surgery, min, median (IQR) (n=225) 135 [110–185] 120 [90–150] <0.001
Length of hospital stay, days, median (IQR) (n=297) 7 [5–11] 3 [2–4] <0.001
Tumor size, mm, median (IQR)
Preoperative studies (n=256) 5.0 (3.9–7.1) 3.6 (3.0–5.0) <0.001
Pathologic studies (n=289) 6.8 (4.0–9.0) 5.0 (3.0–7.0) <0.001
Postoperative complications 21 (12.3) 9 (6.2) 0.064
Adjuvant treatment (n=315) 83 (49.1) 100 (69.5) <0.001
Data as frequencies and percentages in parenthesis unless otherwise stated. *, for the purpose of analysis breast cancer and melanoma 
are included in the “other” category; †, R1 and R2 analyzed in a single category (R0 vs. R1 or R2).
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patients with adrenal metastatic disease undergoing 
adrenalectomy via the laparoscopic route as compared to 
open surgery. Resection of adrenal metastasis through open 
surgery was a significantly associated with a poor survival in 
the bivariate analysis, although this variable was marginally 
significant in the multivariate Cox proportional hazards 
regression model.
Better outcomes were associated with laparoscopic 
adrenalectomy than those obtained after open operations. 
These results may be explained by different factors, 
including a reduced tumor size (both at preoperative and 
histopathological studies), fewer patients requiring extended 
Table 2 Bivariate Cox analysis and multivariate Cox proportional hazard regression analysis
Variables
Bivariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age, years 0.997 (0.983–1.012) 0.732
Gender (male vs. female) 1.105 (0.785–1.554) 0.567
Type of primary tumor
Non-small cell lung cancer (reference category) 1
Colorectal cancer 0.847 (0.513–1.399) 0.516
Renal cancer 0.494 (0.279–0.873) 0.015 0.420 (0.231–0.764) 0.005
Other 1.222 (0.861–1.735) 0.262
Treatment of the primary tumor
Surgery (yes vs. no) 0.350 (0.215–0.570) <0.001 0.328 (0.197–0.545) <0.001
Chemotherapy (yes vs. no) 0.743 (0.543–1.016) 0.063 0.618 (0.435–0.879) 0.007
Radiotherapy (yes vs. no) 0.956 (0.660–1.384) 0.811
Synchronous adrenal metastasis vs. metachronous 1.436 (1.014–2.033) 0.041
Extra-adrenal disease (presence vs. absence) 1.460 (1.030–2.070) 0.033
Site of adrenal metastasis
Left adrenal gland (reference category) 1
Right adrenal gland 0.957 (0.701–1.306) 0.781
Bilateral involvement 0.813 (0.329–2.007) 0.653
Extended adrenalectomy (yes vs. isolated adrenalectomy) 1.549 (1.063–2.257) 0.023
Type of resection (R1/R2 vs. R0) 2.810 (1.896–4.166) <0.001 2.288 (1.520–3.443) <0.001
Duration of surgery (per min)* 1.003 (1.000–1.006) 0.026
Tumor size*
Preoperative (per mm) 1.087 (1.022–1.157) 0.008
Pathological (per mm) 1.062 (1.016–1.110) 0.008
Length of hospital stay (days)* 1.022 (1.001–1.044) 0.041
Postoperative complications (yes vs. no) 1.272 (0.788–2.055) 0.325
Adjuvant treatment after adrenalectomy (yes vs. no) 0.881 (0.645–1.202) 0.424
Open surgery (or converted) 1.538 (1.114–2.124) 0.009 1.367 (0.971–1.925) 0.073
Risk factors for survival in patients undergoing adrenalectomy for solid tumor metastasis. *, increased risk for each year of age, each 
minute of operative time, 1 mm of the tumor, and day of hospital stay. 
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adrenalectomy, a higher number of primary tumors treated 
surgically and patients given chemotherapy for the primary 
malignant lesion, and a higher rate of complete resections 
(R0) in the laparoscopic group as compared to the open 
method. In relation to the effect of completeness of removal 
of adrenal metastasis, analysis of the subset of patients 
who underwent R0 resections, the length of surgical was 
longer for the laparoscopic approach (46 vs. 27 months) 
but the difference was marginally significant. The well-
known benefits of minimally invasive operations already 
reported by other authors (13-15), such as prompt recovery, 
a reduced rate of postoperative complications, and shorter 
length of hospitalization were also documented in our study. 
Laparoscopic adrenalectomy for malignancy is still 
controversial. Although data from small series of patients 
have shown that laparoscopic radical adrenalectomy is 
feasible and can be performed with acceptable outcomes in 
the carefully selected patients with metastases (17,19-22), 
the present study presents a comparison of oncologic results 
in a large cohort of patients undergoing adrenalectomy 
for adrenal metastatic disease, 46% of which were 
operated on through the laparoscopic approach, using 
the transperitoneal route in most cases. Of note, strict 
homogeneous selection criteria and the long follow-up 
period are strengths of the study. However, because this 
was a retrospective, multicenter survey study, no specific 
hypothesis was pre-established Also, laparoscopic or open 
adrenalectomy was performed according to decision of the 
attending endocrine surgeon.
In relation variables associated with survival, renal cancer 
as the type of primary tumor and surgical treatment were 
significantly associated with a better survival, whereas 
survival was negatively affected by synchronous adrenal 
metastasis, extra-adrenal disease, extended adrenalectomy, 
R1/R2 resections, duration of surgery, tumor size, length 
of hospital stay, and open surgery (or converted). In the 
multivariate analysis, risk factors for better survival were 
renal cancer, surgery of the primary tumor, and use of 
chemotherapy, whereas type of resection (R1/R2 vs. R0) was 
associated with a worse prognosis.
On the other hand, the survival rates at 1, 2, 3, and 
5 years after surgery were better for patients treated with 
laparoscopic adrenalectomy than for those undergoing 
open adrenalectomy. However, we found a favorable 5-year 
survival rate of 46% of patients in the laparoscopy group 
and 29.2% of patients in the open surgery group, although 
our series included more than one third of patient with 
extra-adrenal disease at the time of adrenalectomy.
In summary, results of this retrospective multicenter 
review show that laparoscopic adrenalectomy was feasible 
for the treatment of selected patients with metastatic 
adrenal disease. Most importantly, this surgical approach 
was associated with a significantly longer survival as 
compared to open adrenalectomy, probably in relation to a 
higher number of R0 resections.
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